Stocks in Focus: Aurobindo Pharma, GHV Infra Projects, and Others

The GIFT Nifty futures, which are an early indicator of the Nifty50 index stocks, were trading lower by 28 points at 25,418, indicating that the domestic benchmark indices are likely to make a negative start on Friday. 

Earlier on Thursday, 19 February, the domestic benchmark indices S&P BSE Sensex crashed by 1,236 points or 1.48%, and settled at 82,498, while the Nifty50 traded 1.41% lower or 365 points, closing at 25,454.

Here are some stocks that are likely to remain in focus on 20 February.

Aurobindo Pharma: Aurobindo Pharma has received tax demand orders totalling Rs 169.83 crore from the Goods and Services Tax (GST) Department concerning previously granted refunds. The disputed amount includes Rs 84.91 crore in GST and an equivalent penalty. The company received the orders on 18 February 2026.

GHV Infra Projects: GHV Infra Projects has won a work order worth approximately Rs 123 crore from Enmas EPC Power Projects. The company will supply materials for 28.83 MWp grid-connected rooftop solar plants for 14,416 SC and ST consumers, as per its regulatory filing.

Texmaco Rail & Engineering: Texmaco Rail & Engineering has entered into a Joint Venture Shareholders’ Agreement with Rail Vikas Nigam Limited (RVNL) to develop India’s next-generation rolling stock hub and strengthen its global rail EPC presence.

Nykaa: FSN E-Commerce Ventures, the parent company of Nykaa, has partnered with South Korea’s APR Corporation to introduce the skincare brand Medicube in India. The launch marks Medicube’s omnichannel debut in the country. The brand, known globally for its viral collagen, PDRN, and pore-care products, will be available exclusively on Nykaa’s online platforms and select offline stores starting 20 February.

Novartis India: Novartis AG has signed an agreement to sell its 70.68% stake in Novartis India to WaveRise Investments, ChrysCapital Fund X, and Two Infinity Partners. Under the transaction, the acquirers will purchase 1.74 crore shares of Novartis India from Novartis AG, marking a significant change in the ownership structure of the Indian subsidiary.

Pace Digitek: Pace Digitek has secured an advance Letter of Award worth ₹89 crore from RailTel Corporation of India. The company will supply, install, and commission an IP-based video surveillance system in LHB coaches. The contract includes a three-year warranty and a subsequent five-year Comprehensive Annual Maintenance Contract (CAMC) for a RailTel customer on a back-to-back basis.

RailTel Corporation of India: RailTel Corporation of India has received a Letter of Acceptance (LoA) valued at Rs 35.54 crore for a railway signalling project. The company will complete the work within 24 months from the LoA date. The project covers the provision of MSDAC and related works, along with indoor modifications at EI/RRI/PI stations in the Prayagraj division of North Central Railway.

Zydus Lifesciences: The US Food and Drug Administration (USFDA) conducted a Pre-Approval Inspection (PAI) of injectable medical devices at Zydus Lifesciences’ Unit 9 facility at Zydus Biotech Park, Ahmedabad, from 16 to 19 February. The regulator concluded the inspection without any observations.

Discover the next big investment! Tradz by EquityPandits’ IPO screener helps you identify promising initial public offerings. Download Tradz by EquityPandit and get ahead of the curve! Sign Up Now & Find Your Next IPO Gem!

The post Stocks in Focus: Aurobindo Pharma, GHV Infra Projects, and Others appeared first on Equitypandit.